

Supplementary material

Pathogen identification and outcome in adult patients with community-acquired pneumonia in Switzerland: findings from the Swiss CAPNETZ cohort study

Authors and affiliations

Samuel Etienne^{1,2 *}, Werner C. Albrich^{3 *}, Mathias W. Pletz⁴, Marcus Panning⁵, Vivian Suarez Domenech¹, Frank Eberhardt⁶, Grit Barten-Neiner^{6,7}, Daiana Stolz⁸, for the CAPNETZ study group

¹Clinic of Respiratory Medicine and Pulmonary Cell Research, University Hospital of Basel, Basel, Switzerland

²Unit for Lung & Airway Research, Institute of Environmental Medicine, Karolinska Institute, and Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden

³Division of Infectious Diseases, Infection Prevention and Travel Medicine, Cantonal Hospital St. Gallen, St. Gallen, Switzerland

⁴Institute of Infectious Diseases and Infection Control and Center for Sepsis Care and Control (CSCC), Jena University Hospital, Jena, Germany

⁵Institute of Virology, Medical Center and Faculty of Medicine, University of Freiburg, Freiburg, Germany

⁶CAPNETZ STIFTUNG, Hannover, Germany


⁷German Centre for Lung Research, DZL, Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Hannover, Germany

⁸Clinic of Respiratory Medicine, Medical Center and Faculty of Medicine, University of Freiburg, Freiburg, Germany

*These authors contributed equally to this work.

Corresponding author

Samuel Etienne, MD, email : samuel.etienne@ki.se



Supplementary fig. 1 Proportions of microbiological tests with positive results.

	<i>Bacterial pathogen only</i>	<i>Bacterial-bacterial co-infection</i>	<i>Bacterial-viral co-infection</i>	<i>Viral pathogen only</i>	<i>Other*</i>	<i>S. pneumoniae</i>	<i>H. influenzae</i>	<i>L. pneumophila</i>	<i>Human rhinovirus</i>	<i>SARS-CoV-2</i>	<i>Pseudomonas aeruginosa</i>
Mortality											
28 days	3/95 (3.2)	0/16 (0)	0/31 (0)	2/35 (5.7)	2/3 (66.6)	1/63 (1.6)	2/29 (6.9)	0/22 (0)	0/21 (0)	2/21 (9.5)	0/16 (0)
180 days	6/95 (6.3)	1/16 (6.3)	0/31 (0)	3/35 (8.6)	2/3 (66.6)	2/63 (3.2)	3/29 (10.3)	0/22 (0)	0/21 (0)	2/21 (9.5)	1/16 (6.3)
ICU admission											
Overall	7/95 (7.4)	2/16 (12.5)	1/31 (3.2)	2/35 (5.7)	2/3 (66.6)	7/63 (11.1)	3/29 (10.3)	2/22 (9.1)	0/21 (0)	1/21 (4.8)	0/16 (0)
NIV	3/95 (3.2)	0/16 (0)	1/31 (3.2)	1/35 (2.9)	0/3 (0)	2/63 (3.2)	1/29 (3.4)	1/22 (4.5)	1/21 (4.8)	0/21 (0)	0/16 (0)
Intubation	0/95 (0)	0/16 (0)	0/31 (0)	1/35 (2.9)	1/3 (33.3)	1/63 (1.6)	0/29 (0)	0/22 (0)	0/21 (0)	1/21 (4.8)	0/16 (0)

Supplementary table 1 Mortality, ICU admission and mechanical ventilation rates according to identified pathogen. * Other includes: one patient with a bacterial-fungal co-infection (*E. coli*, *S. pneumoniae* and *Aspergillus* spp), one patient with a viral-fungal co-infection (Rhinovirus/Enterovirus and *Aspergillus fumigatus*) and one patient with a fungal infection (*Aspergillus* spp).

